Future experiments combining MCL1 inhibitors with multiple ICIs (anti-PD-1 + anti-CTLA4 or anti-PD-1 + anti-LAG3) may help identify optimal treatment strategies for melanoma, as well as many other tumors where MDSCs prevent the efficacy of conventional therapies. Here, MCL1 is linked to melanoma.